BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Skin cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1
275 results:

  • 1. Immunohistochemical and Molecular Characteristics of Anogenital Papillary Hidradenomas.
    Karpathiou G; Sim A; Picot T; Mekhzoumi K; Chauleur C; Péoc'h M
    Am J Dermatopathol; 2024 Feb; 46(2):79-82. PubMed ID: 38055985
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Clinical, Morphologic, and Molecular Features of Benign and Intermediate-grade Melanocytic Tumors With Activating Mutations in map2k1.
    Fumero-Velázquez M; Hagstrom M; Dhillon S; Geraminejad T; Olivares S; Donati M; Nosek D; Waldenbäck P; Kazakov D; Sheffield BS; Tron VA; Gerami P
    Am J Surg Pathol; 2023 Dec; 47(12):1438-1448. PubMed ID: 37773074
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Determination of T-cell clonality and expression profiles of Toll-like receptors signaling pathway genes and related miRNAs in patients with mycosis fungoides.
    Seçme M; Dodurga Y; Demirkan NÇ; Kaçar N; Günel NS; Açıkbaş İ
    Gene; 2024 Jan; 891():147825. PubMed ID: 37748629
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Computational biology and in vitro studies for anticipating cancer-related molecular targets of sweet wormwood (Artemisia annua).
    Dawood H; Celik I; Ibrahim RS
    BMC Complement Med Ther; 2023 Sep; 23(1):312. PubMed ID: 37684586
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. NTRK expression is common in xanthogranuloma and is associated with the solitary variant.
    Umphress B; Kuhar M; Kowal R; Alomari AK; Baldridge LA; Ross AJ; Warren SJ
    J Cutan Pathol; 2023 Nov; 50(11):991-1000. PubMed ID: 37580954
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. map2k1-mutated melanocytic tumors have reproducible histopathologic features and share similarities with melanocytic tumors with BRAF V600E mutations.
    Alomari AK; Harms PW; Andea AA; Warren SJ
    J Cutan Pathol; 2023 Dec; 50(12):1083-1093. PubMed ID: 37565534
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
    Augustyn K; Joseph J; Patel AB; Razmandi A; Ali AN; Tawbi HA
    Melanoma Res; 2023 Oct; 33(5):406-416. PubMed ID: 37534686
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Protein phosphatase 6 regulates trametinib sensitivity, a mitogen-activated protein kinase kinase (MEK) inhibitor, by regulating mek1/2-ERK1/2 signaling in canine melanoma cells.
    Yamamoto M; Fujiwara N
    J Vet Med Sci; 2023 Sep; 85(9):977-984. PubMed ID: 37495516
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response.
    Randic T; Magni S; Philippidou D; Margue C; Grzyb K; Preis JR; Wroblewska JP; Nazarov PV; Mittelbronn M; Frauenknecht KBM; Skupin A; Kreis S
    Cell Rep; 2023 Jul; 42(7):112696. PubMed ID: 37379213
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Computational pharmacology profiling of borapetoside C against melanoma.
    Bhattacharya K; Khanal P; Patil VS; Dwivedi PSR; Chanu NR; Chaudhary RK; Deka S; Chakraborty A
    J Biomol Struct Dyn; 2024 Apr; 42(6):3233-3248. PubMed ID: 37203884
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Trametinib in Patients With
    Wisinski KB; Flamand Y; Wilson MA; Luke JJ; Tawbi HA; Hong F; Mitchell EP; Zwiebel JA; Chen H; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Behrens RJ; Pennington KP; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    JCO Precis Oncol; 2023 Apr; 7():e2200421. PubMed ID: 37053535
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Natural killer cells suppress human cutaneous squamous cell carcinoma cancer cell survival and tumor growth.
    Adhikary G; Heipertz EL; Preradovic M; Chen X; Xu W; Newland JJ; Kaur N; Vemuri MC; Eckert RL
    Mol Carcinog; 2023 Jun; 62(6):845-854. PubMed ID: 36994661
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Spitz Tumor With SQSTM1::NTRK2 Fusion: A Clinicopathological Study of 5 Cases.
    Mansour B; Vanecek T; Kastnerova L; Nosek D; Kazakov DV; Donati M
    Am J Dermatopathol; 2023 May; 45(5):306-310. PubMed ID: 36939120
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Optically activated mek1/2 inhibitors (Opti-MEKi) as potential antimelanoma agents.
    Hao C; Li X; Wang Z; Liu L; He F; Pan Z
    Eur J Med Chem; 2023 May; 251():115236. PubMed ID: 36924668
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Response and Resistance to Trametinib in map2k1-Mutant Triple-Negative Melanoma.
    Krebs FS; Moura B; Missiaglia E; Aedo-Lopez V; Michielin O; Tsantoulis P; Bisig B; Trimech M; Zoete V; Homicsko K
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901951
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis.
    Whitlock JA; Geoerger B; Dunkel IJ; Roughton M; Choi J; Osterloh L; Russo M; Hargrave D
    Blood Adv; 2023 Aug; 7(15):3806-3815. PubMed ID: 36884302
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and mek1/2.
    Wang P; Jia X; Lu B; Huang H; Liu J; Liu X; Wu Q; Hu Y; Li P; Wei H; Liu T; Zhao D; Zhang L; Tian X; Jiang Y; Qiao Y; Nie W; Ma X; Bai R; Peng C; Dong Z; Liu K
    Signal Transduct Target Ther; 2023 Mar; 8(1):96. PubMed ID: 36872366
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. An update on genomic aberrations in Spitz naevi and tumours.
    Hagstrom M; Fumero-Velázquez M; Dhillon S; Olivares S; Gerami P
    Pathology; 2023 Mar; 55(2):196-205. PubMed ID: 36631338
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma.
    Takano K; Munehira Y; Hatanaka M; Murakami R; Shibata Y; Shida T; Takeuchi K; Takechi S; Tabata T; Shimada T; Kishikawa S; Matsui Y; Ubukata O; Seki T; Kaneta Y
    Mol Cancer Ther; 2023 Mar; 22(3):317-332. PubMed ID: 36622773
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Genomics and Epigenomics in the Molecular Biology of Melanoma-A Prerequisite for Biomarkers Studies.
    Zob DL; Augustin I; Caba L; Panzaru MC; Popa S; Popa AD; Florea L; Gorduza EV
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614156
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 14.